GSK's Omjjara wins EC approval

The European Commission (EC) has granted marketing authorization for Omjjara (momelotinib), a once-a-day, oral JAK1/JAK2 and activin A receptor type 1 (ACVR1) inhibitor.

GSK's (LSE: GSK) drug is the first authorized medicine in the European Union (EU) for disease-related splenomegaly or symptoms in adults with moderate to severe anemia who have primary myelofibrosis, post polycythemia vera myelofibrosis or post essential thrombocythemia myelofibrosis and who are Janus kinase (JAK) inhibitor naïve or have been treated with ruxolitinib.

"The authorization of Omjjara brings a new treatment option with a differentiated mechanism of action to these patients in the EU"